| Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology JP Radich, M Deininger, CN Abboud, JK Altman, E Berman, R Bhatia, ... Journal of the National Comprehensive Cancer Network 16 (9), 1108-1135, 2018 | 244 | 2018 |
| Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology MW Deininger, NP Shah, JK Altman, E Berman, R Bhatia, B Bhatnagar, ... Journal of the National Comprehensive Cancer Network 18 (10), 1385-1415, 2020 | 223 | 2020 |
| Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single … B Bhatnagar, S Gilmore, O Goloubeva, C Pelser, M Medeiros, S Chumsri, ... Springerplus 3, 1-6, 2014 | 139 | 2014 |
| Effectiveness of integrated palliative and oncology care for patients with acute myeloid leukemia: a randomized clinical trial A El-Jawahri, TW LeBlanc, A Kavanaugh, JA Webb, VA Jackson, ... JAMA oncology 7 (2), 238-245, 2021 | 110 | 2021 |
| XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase IIα to the nucleus P Ranganathan, T Kashyap, X Yu, X Meng, TH Lai, B McNeil, ... Clinical Cancer Research 22 (24), 6142-6152, 2016 | 85 | 2016 |
| NCCN guidelines insights: chronic myeloid leukemia, version 1.2017 A Pallera, JK Altman, E Berman, CN Abboud, B Bhatnagar, P Curtin, ... Journal of the National Comprehensive Cancer Network 14 (12), 1505-1512, 2016 | 72 | 2016 |
| Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome AS Kittai, DA Bond, B William, A Saad, S Penza, Y Efebera, K Larkin, ... Blood Advances 4 (19), 4648-4652, 2020 | 66 | 2020 |
| Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia P Ranganathan, X Yu, R Santhanam, J Hofstetter, A Walker, K Walsh, ... Blood, The Journal of the American Society of Hematology 125 (17), 2689-2692, 2015 | 63 | 2015 |
| Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia B Bhatnagar, AK Eisfeld, D Nicolet, K Mrózek, JS Blachly, S Orwick, ... British journal of haematology 175 (2), 226-236, 2016 | 62 | 2016 |
| NCCN guidelines insights: acute lymphoblastic leukemia, Version 1.2019: featured updates to the NCCN guidelines PA Brown, M Wieduwilt, A Logan, DJ DeAngelo, ES Wang, A Fathi, ... Journal of the National Comprehensive Cancer Network 17 (5), 414-423, 2019 | 60 | 2019 |
| Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy B Bhatnagar, VH Duong, TS Gourdin, ML Tidwell, C Chen, Y Ning, ... Leukemia & lymphoma 55 (7), 1533-1537, 2014 | 60 | 2014 |
| Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease … MR Litzow, Z Sun, E Paietta, RJ Mattison, HM Lazarus, JM Rowe, ... Blood 140 (Supplement 2), LBA-1-LBA-1, 2022 | 54 | 2022 |
| Complete responses in relapsed/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of XmAb14045, a CD123 x CD3 T cell-engaging bispecific antibody … F Ravandi, A Bashey, JM Foran, W Stock, R Mawad, W Blum, MW Saville, ... Blood 132, 763, 2018 | 51 | 2018 |
| Poor survival and differential impact of genetic features of black patients with acute myeloid leukemia B Bhatnagar, J Kohlschmidt, K Mrózek, Q Zhao, JL Fisher, D Nicolet, ... Cancer discovery 11 (3), 626-637, 2021 | 50 | 2021 |
| AML with myelodysplasia-related changes: development, challenges, and treatment advances KL Koenig, KD Sahasrabudhe, AM Sigmund, B Bhatnagar Genes 11 (8), 845, 2020 | 49 | 2020 |
| Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia N Jain, W Stock, A Zeidan, E Atallah, J McCloskey, L Heffner, B Tomlinson, ... Blood advances 4 (3), 449-457, 2020 | 47 | 2020 |
| Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia AR Walker, H Wang, K Walsh, B Bhatnagar, S Vasu, R Garzon, ... Leukemia & lymphoma 57 (9), 2100-2108, 2016 | 47 | 2016 |
| Entospletinib in combination with induction chemotherapy in previously untreated acute myeloid leukemia: response and predictive significance of HOXA9 and MEIS1 expression AR Walker, JC Byrd, JS Blachly, B Bhatnagar, AS Mims, S Orwick, TL Lin, ... Clinical Cancer Research 26 (22), 5852-5859, 2020 | 41 | 2020 |
| Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study B Bhatnagar, Q Zhao, AS Mims, S Vasu, GK Behbehani, K Larkin, ... Leukemia & lymphoma 61 (2), 387-396, 2020 | 40 | 2020 |
| Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML JY Jeon, Q Zhao, DR Buelow, M Phelps, AR Walker, AS Mims, S Vasu, ... Investigational new drugs 38, 340-349, 2020 | 35 | 2020 |
